Ubs Group Ag Tiziana Life Sciences LTD Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Tiziana Life Sciences LTD stock. As of the latest transaction made, Ubs Group Ag holds 610 shares of TLSA stock, worth $567. This represents 0.0% of its overall portfolio holdings.

Number of Shares

610

Previous 51,617 98.82%

Holding current value

$567

Previous $47,000 100.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$0.81 - $1.45 $41,315 - $73,960	-51,007 Reduced 98.82%	610 $0
Q2 2024 Aug 13, 2024	BUY	$0.43 - $1.01 $8,498 - $19,960	19,763 Added 62.04%	51,617 $47,000
Q1 2024 May 13, 2024	BUY	$0.42 - $0.61 $1,383 - $2,009	3,295 Added 11.54%	31,854 $14,000
Q4 2023 Feb 09, 2024	BUY	$0.55 - $0.85 $15,316 - $23,671	27,849 Added 3922.39%	28,559 $15,000
Q3 2023 Nov 09, 2023	BUY	$0.6 - $0.82 $54 - $73	90 Added 14.52%	710 $0
Q2 2023 Aug 11, 2023	SELL	$0.65 - $1.29 $3,634 - $7,213	-5,592 Reduced 90.02%	620 $0
Q1 2023 May 12, 2023	SELL	$0.51 - $1.1 $6,907 - $14,898	-13,544 Reduced 68.56%	6,212 $6,000
Q4 2022 Feb 08, 2023	SELL	$0.56 - $0.78 $1,112 - $1,549	-1,987 Reduced 9.14%	19,756 $11,000
Q3 2022 Nov 10, 2022	BUY	$0.55 - $0.83 $8,972 - $13,539	16,313 Added 300.42%	21,743 $16,000
Q2 2022 Aug 10, 2022	BUY	$0.66 - $1.06 $3,007 - $4,830	4,557 Added 521.99%	5,430 $4,000
Q1 2022 May 16, 2022	SELL	$0.62 - $1.25 $1,109 - $2,236	-1,789 Reduced 67.21%	873 $1,000
Q4 2021 Feb 14, 2022	BUY	$0.89 - $1.66 $2,369 - $4,418	2,662 New	2,662 $3,000

Others Institutions Holding TLSA

# of Institutions

Shares Held

1.94M

Call Options Held

19.2K

Put Options Held

View Full List

About Tiziana Life Sciences Ltd

Ticker TLSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,273,000
Market Cap $95.1M
Description
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, m...

More about TLSA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account